HMGB1 and early-onset autosomal dominant Alzheimer disease: For example, an anti-HMGB1 monoclonal antibody (mAb) has been developed and was shown to be effective in treating many animal models of central nervous system (CNS) diseases, such as Parkinson’s disease, Alzheimer’s disease, and stroke (Yang et al., 2015b).